Is vTv Therapeutics Inc (VTVT) overvalued? · rev $36.8M
vTv Therapeutics Inc (VTVT) is a biotechnology company listed on NASDAQ.
This page asks whether vTv Therapeutics Inc (VTVT) looks expensive on cached numbers — not a short thesis.
Latest reported VTVT revenue for 2026-06-30 was $36.8M. Net income was $11.1M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. VTVT currently screens at market cap $133.9M.
VTVT currently screens at market cap $133.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VTVT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VTVT stock page for the full model, not this heading.
Not investment advice.